TY - JOUR T1 - Single-cell Transcriptome Analysis Reveals an Anomalous Epithelial Variation and Ectopic Inflammatory Response in Chronic Obstructive Pulmonary Disease JF - medRxiv DO - 10.1101/2020.12.03.20242412 SP - 2020.12.03.20242412 AU - Naoaki Watanabe AU - Jun Nakayama AU - Yu Fujita AU - Yutaro Mori AU - Tsukasa Kadota AU - Iwao Shimomura AU - Takashi Ohtsuka AU - Koji Okamoto AU - Jun Araya AU - Kazuyoshi Kuwano AU - Yusuke Yamamoto Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/07/2020.12.03.20242412.abstract N2 - Chronic obstructive pulmonary disease (COPD) is a progressive disease that obstructs the airflow from the lungs, and tobacco smoking is the major cause of COPD. Here, we applied single-cell RNA sequencing to analyze COPD pathogenesis in COPD patients, non-COPD smokers and never-smokers and investigated the disease progression at single-cell resolution. By single-cell transcriptome analysis, COPD was characterized by shifts in the stromal, immune system and epithelial cell compositions. While epithelial components in never-smokers were relatively uniform, the smoker groups presented with extensive heterogeneity in epithelial cells, particularly in the alveolar type II (AT2) lineages. We identified a subpopulation of AT2 epithelial cells that emerged in smokers, such as COPD patients, and specifically expressed a series of chemokines and PD-L1. A trajectory analysis revealed that the inflammatory AT2 cell subpopulation followed a unique differentiation path, and a prediction model of cell-to-cell interactions inferred increased intercellular networks of inflammatory AT2 cells with immune and stromal cell populations. Thus, our analysis reveals a unique cellular differentiation pathway and function underlying the biological and clinical characteristics of COPD pathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Project for MEXT KAKENHI (Grant-in-Aid for Young Scientists (A); grant number: 17H04991, Grant-in-Aid for JSPS Fellows: 20J01794), Research grant from The Naito Foundation, GSK Japan Research Grant, Mochida Memorial Foundation for Medical and Pharmaceutical Research, and Takeda Science Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human lung tissue from never-smokers, non-COPD smokers, and patients with COPD was obtained from patients undergoing pneumonectomy or lobectomy for primary lung cancer. The diagnosis of COPD was established using the Global Initiative for Chronic Obstructive Lung Disease criteria. Informed consent was obtained from all surgical participants as part of an approved ongoing research protocol by the ethical committee of The Jikei University School of Medicine (#20-153 (5443)).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBulk RNA-seq data were submitted to the NCBI GEO database accession number GSE162154. ER -